정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 492 | Recruiting | Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial | Liver Cirrhosis | Drug: Placebo Drug: Esomeprazole 20mg |
Phase 4 | Universitatsklinikum Hamburg-Eppendorf, German Federal Ministry of Education and Research, University Hospital Heidelberg | OTHER | 476 | All | 18 Years | University Medical Center Hamburg-Eppendorf, Hamburg, Germany |
| 491 | Completed | STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19 | Covid19 | Drug: Brensocatib Drug: Placebo |
Phase 3 | University of Dundee, NHS Tayside, Insmed Incorporated | OTHER | 406 | All | 16 Years | NHS Grampian, Aberdeen, United Kingdom Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom Cardiff & Vale University Health Board, Cardiff, United Kingdom NHS Tayside, Dundee, United Kingdom NHS Fife, Dunfermline, United Kingdom Frimley Health NHS Foundation Trust, Frimley, United Kingdom Princess Alexandra Hospital NHS Trust, Harlow, United Kingdom NHS Highland, Inverness, United Kingdom NHS Forth Valley, Larbert, United Kingdom University Hospitals of Leicester NHS Trust, Leicester, United Kingdom Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom University Hospitals North Midlands NHS Trust, Stoke-on-Trent, United Kingdom NHS Lanarkshire, Wishaw, United Kingdom |
| 490 | Completed | Stopping ACE-inhibitors in COVID-19 | COVID-19 | Drug: ACE inhibitor, angiotensin receptor blocker | Phase 4 | Medical University Innsbruck, Ludwig-Maximilians - University of Munich, Deutsches Zentrum fur Herz-Kreislauf-Forschung (DZHK) | OTHER | 216 | All | 18 Years | Medical University Innsbruck, University Hospital of Internal Medicine III, Innsbruck, Tyrol, Austria Medical University of Graz, Graz, Austria Landeskrankenhaus Hall, Hall In Tirol, Austria Medical University Innsbruck, Intensive Care and Emergency Medicine Department, Innsbruck, Austria Medical University Innsbruck, University Hospital of Internal Medicine II, Innsbruck, Austria Medical University Innsbruck, University Hospital of Internal Medicine IV, Innsbruck, Austria Medical University Innsbruck, University Hospital of Internal Medicine I, Innsbruck, Austria Medical University Innsbruck, University Hospital of Internal Medicine V, Innsbruck, Austria Klinikum Klagenfurt, Klagenfurt, Austria Bezirkskrankenhaus Kufstein, Kufstein, Austria Klinikum Lienz, Lienz, Austria Bezirkskrankenhaus St. Johann, Sankt Johann In Tirol, Austria Bezirkskrankenhaus Schwaz, Schwaz, Austria Krankenhaus St. Vinzenz Zams, Zams, Austria LMU Klinikum, Medizinische Klinik I, Munich, Bavaria, Germany University Hospital Aachen, Aachen, Germany University Hospital Augsburg, Augsburg, Germany Asklepios Stadtklinik Bad Tolz, Bad Tolz, Germany Klinikum Dachau, Dachau, Germany University Hospital Erlangen, Erlangen, Germany University Hospital Essen, Essen, Germany University of Freiburg, Freiburg, Germany Klinikum Memmingen, Memmingen, Germany LMU Klinikum, Medizinische Klinik III, Munich, Germany LMU Klinikum, Medizinische Klinik II, Munich, Germany LMU Klinikum, Medizinische Klinik IV, Munich, Germany Munchen Klinik Bogenhausen und Schwabing, Munich, Germany Rotkreuzklinikum Munich, Munich, Germany Krankenhaus Muhldorf, Muhldorf, Germany Klinikum Rosenheim, Rosenheim, Germany Krankenhaus Weiden, Weiden, Germany |
| 489 | Active, not recruiting | Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines. | COVID-19 Vaccines | Drug: Gam-COVID-Vac (rAd26) / Gam-COVID-Vac (rAd5) | Phase 2 | Ministerio de Salud de Ciudad Autonoma de Buenos Aires | OTHER_GOV | 348 | All | 21 Years ~ 65 Years | Ministerio de Salud de la Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, CBA, Argentina Ministerio de Salud de la Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina |
| 488 | Recruiting | Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol) | Covid-19 | Drug: open label BSS (pepto Bismol) | Phase 4 | University of Louisville, Procter and Gamble | OTHER | 35 | All | 18 Years ~ 85 Years | University of Louisville, Louisville, Kentucky, United States |
| 487 | Not yet recruiting | Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination | Covid19 | Drug: MRNA-1273 | Phase 2 | Maria Joyera Rodriguez | OTHER | 80 | All | 18 Years | |
| 486 | Not yet recruiting | Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients | Symptomatic COVID-19 Infection Laboratory-Confirmed | Biological: Virus-specific Cytotoxic T-lymphocytes | Phase 1 | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | OTHER | 30 | All | 18 Years | M D Anderson Cancer Center, Houston, Texas, United States |
